TEC Edmonton is delighted to announce the top 3 finalists in its VenturePrize business plan competition (Fast Growth category): Alieo Games, Pogo Car Share and Sensassure.

Now in its 13th year, TEC VenturePrize is an annual business plan competition for early stage Alberta technology entrepreneurs.

For over a decade, VenturePrize participants have shown proven success, making VenturePrize and TEC Edmonton recognized as key drivers of Alberta economic diversification.

Participants submit their business plans and compete for a prize package of cash and in-kind services to help grow their companies. The Fast Growth Grand Prize Winner receives over $80,000 in cash and in-kind services, and the two Runners-Up receiver over $30,000 in cash and in-kind services.

Our finalists

Alieo Games

Alieo Games is an educational technology company that recently launched COW, a writing app for students and teachers in K-12. COW provides a safe and fun space for students to practice writing (building writing fluency and vocabulary) and to share their work with classmates. For teachers, COW uses text analysis to provide useful feedback that they can use to customize their lesson plans to meet the specific needs of their students.

Alieo Games tells a great story of University of Alberta student innovation that has already succeeded in winning several business competitions. Their writing app COW is being used by students in grades 2-10.

Pogo CarShare


Pogo CarShare is Edmonton’s first car sharing service. Founded and managed locally, Pogo provides members 24/7 access to a pool of vehicles located within a central zone in our city on a simple pay-as-you-go basis. Cars can be located, reserved and opened using the Pogo app. Customers only pay for the exact amount of time they use the vehicle, and gas, insurance, parking, and maintenance are all included in the flat, per-minute rate.

Convenient, affordable and environmentally sustainable, Pogo CarShare introduces a greater freedom of transportation options to Edmontonians, and is estimated to increase public transportation use by three times per week.



Sensassure is a wearable tech startup that was founded as part of Canada’s Next 36, a national tech incubator program. Sensassure’s sensor solution for the incontinent elderly tracks if they’ve wet themselves and alerts nursing staff when changes are required. Sensassure helps restore dignity to those who suffer from incontinence by automating existing manual care processes, leading to timely changes that prevent secondary conditions from developing.

Sensassure’s technology addresses the ever present needs of senior care and provides an innovative new technology to improve quality of care – one that can also be used in a home setting.

Winners of the TEC VenturePrize Fast Growth, Student and TELUS Information & Communication Technology (ICT) competition streams will be announced at the VenturePrize Awards Celebration on April 29, 2015, at the Edmonton Shaw Conference Centre.

The event brings together the region’s business and innovation community, highlighting the next generation of Alberta’s technology entrepreneurs.

Starting April 1st, the public will be able to vote for their favorite Fast Growth Finalist online. The winner will receive the Edmonton Journal People’s Choice Award, also to be presented at the VenturePrize Awards Event on April 29.

For more information on VenturePrize, or to purchase tickets for the VenturePrize Awards Celebration, visit www.ventureprize.com.

Media Contact:
Erik Einsiedel
TEC Edmonton
Phone: (780) 248-5886
Email: erik.einsiedel@tecedmonton.com


TEC Edmonton’s Technology Management team offers expert advice on intellectual property matters which often lead to new patents, licensing agreements and company spin-offs.

New Patents


Bacterial Endotoxin for the Prevention of Metabolic Disorders and Bacterial Infections
Researcher: Dr. Burim Ametaj

On December 30, 2014, Dr. Burim Ametaj of the University of Alberta’s Department of Agricultural Food and Nutritional Science received a United State patent titled “Bacterial Endotoxin for the Prevention of Metabolic Disorders and Bacterial Infections” (serial no. 8,920,814).

Ruminant diets rich in starch lead to the development of metabolic disorders by changing the gastrointestinal microflora from fibre-digesting bacteria to starch-digesting bacteria. These starch-digesting bacteria, mostly Gram-negative bacteria, release large amounts endotoxins that are translocated into the host’s blood circulation triggering multiple perturbations associated with a variety of periparturient diseases such as ketosis, fatty liver, laminitis, displaced abomasum, milk fever, downer cow syndrome, udder edema, metritis, retained placenta, infertility and mastitis.

The University of Alberta researcher discovered that oral administration of Gram-negative bacterial endotoxin or lipopolysaccharide to dairy cows during the dry off period was effective in preventing the development of several of the those diseases.

With support from TEC Edmonton, our Calgary counterpoint Innovate Calgary introduced its provincial-wide Kinetica Energy Technology Accelerator to Northern Alberta on Thursday, March 5, 2015 at the University of Alberta.

TEC Edmonton and Innovate Calgary have embarked on a unique partnership. With funding from the federal government’s Canada Accelerator and Incubator Program (CAIP), the two city-based technology business accelerators are supporting each other in offering province-wide technology accelerator programs in their respective areas of  expertise.

TEC Edmonton’s TEC Health Accelerator concentrates on growing Alberta’s new and early-stage health-related companies, in building bridges between those companies and the Canadian health industry, investors and Alberta’s health delivery system. The University of Alberta is known for its health-related research and commercialization opportunities. Metropolitan Edmonton also has a cluster of off-campus health-related technology companies.

Kinetica, using a slightly different business model, will enhance linkages between energy-related small-to-medium-sized enterprises, startup companies, investors and the industry at large.

Kinetica is using a push-pull model, says Kinetica program director Kevin Frankowski, finding out what the energy industry is looking for, developing a “shopping list”, scouting for new companies with solutions, assessing and mentoring such companies toward commercialization of their product.

Kinetica’s focus areas within the energy sector are hydrocarbon recovery, energy transport, carbon capture/re-use/disposal and renewables.

“Industry wants de-risked, field-trial ready solutions for their key challenges,” Frankowski told the  audience gathered at the introduction. “Our job is to shorten the traditionally long development cycle of such products, to guide our Kinetica clients through the ‘valley of death’  (scale up, testing, pre-field trials, then pilot and field trials)  leading to commercial use.”

For Kinetica to take an early-stage company into its program, the company must have a product, service or solution on the “challenge list” that Kinetic is compiling from the industry.

The candidate company must be at a “beyond-concept”. Commercialization must be a top priority and a prime motivation.

Kinetica is not, stressed Frankowski, a technology developer, broker, venture fund or industry association.  It scouts for companies with solutions to energy industry needs, then guides and mentors those companies on the path to commercialization and profitability.

To learn more about Kinetica’s programs and mandate, visit kineticaventures.com.  or contact Kinetica’s Northern Alberta representative Lorena Forester at 780-966-4809, info@kineticaventures.com.

University of Alberta researchers can learn more about the program through TEC Edmonton Technology Management VP  Jayant Kumar, jayant.kumar@tecedmonton.com, 780-492-9806.

Janssen_Prof_RGBMarch 10, 2015 – Edmonton, AB – Business incubator TEC Edmonton has announced a strategic partnership with Janssen Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, along with Johnson & Johnson Medical Products. The partnership will introduce new opportunities for Alberta health care professionals, researchers and patients thanks to the TEC Health Accelerator.

Led by TEC Edmonton in partnership with Innovate Calgary, the TEC Health Accelerator is a new initiative designed to accelerate the growth of Alberta biotechnology companies and connect community entrepreneurs with medical and scientific researchers in Alberta. The program also bridges the gap between investors, Alberta startup companies, Alberta Health Services (AHS), potential industry partners and large animal/health agriculture companies. By connecting these entities, TEC Health Accelerator aims to broker major financing, partnership deals and revenue growth for clients in the healthcare space.

Janssen Inc. is a leading healthcare company that offers innovative products in areas of high unmet medical need like oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.

A division of Johnson & Johnson Inc., Johnson & Johnson Medical Products markets medical devices and diagnostic solutions for use by health-care professionals and hospitals in Canada. The portfolio includes medical devices for minimally invasive and open surgical procedures, devices for women’s health, infection prevention and control, cardiovascular and neurovascular diagnostics and treatment, and breast implants for augmentation and reconstruction.

“We’re very excited to partner with Janssen and Johnson & Johnson Medical Products and their proven track record for top quality medical products and services,” said Chris Lumb, TEC Edmonton CEO. “Their support of TEC Health Accelerator means better ways to connect the Alberta health and business communities.”

Named 2014 “Incubator of the Year” by Startup Canada and “10th Best University Business Incubator in the World” by the 2014 University Business Index (UBI), TEC Edmonton launched the new TEC Health Accelerator on November 27, 2014.

For more information, visit www.tecedmonton.com or contact:

Randy Yatscoff
Executive VP, TEC Edmonton
Phone: (780) 492-5744
Email: randy.yatscoff@tecedmonton.com

Jason Ding
Program Director, TEC Health Accelerator
Phone: (780) 492-8977
Email: Jason.Ding@tecedmonton.com


The staff of TED Edmonton joins so many in Alberta’s innovation and academic communities in mourning the sudden passing of Dr. Cy Frank, CEO of Alberta Innovates Health Solutions (AIHS).

“We at TEC Edmonton are feeling incredibly saddened by the news of Dr. Cy Frank’s passing on March 5,” says TEC Edmonton CEO Chris Lumb.

“Cy was a highly respected leader in the health community. In addition to being a clinician, he was known for his work in building community support for system change and optimization of health delivery practices. He demonstrated this by leading changes that resulted in vastly improved efficiency and health outcomes in orthopaedic surgery in the province. Cy was in the midst of leading broader change through his role at Alberta Innovations Health Solution.

“Alberta’s health system will miss Cy’s visionary leadership.”

A full story on Dr. Frank’s career and contribution can be in the Calgary Herald of March 5, 2015, “Medical community mourns loss of innovator Dr. Cy Frank.

TEC Edmonton, our clients and TEC Centre tenants have been in the news of late.

Global Edmonton Jan. 21, 2015
An invention to help care for wounds
Caring for wounds costs the Canadian health care system $3.9 billion a year. TEC Centre tenant Exciton has a solution that’s helping people around the world. Global’s health reporter Su-Ling Goh explains.
Alberta Venture Magazine, print edition, March 2015, story on TEC Edmonton client Champion Petfoods, entitled “Gone to the Dogs: Marinville’s Champion Petfoods has overcome red tape to sell to 72 countries.” 
TEC Edmonton client NanoSpeed just released a news announcement for the expansion of its global distribution agreement with DiaSys Diagnostics Systems. http://www.businesswire.com/news/home/20150302006240/en/NanoSpeed-Announces-Global-Distribution-Partnership-DiaSys-Diagnostics#.VPYkL_nF_lE
LoginRadius_optEdmonton Journal, Gary Lamphier business columnist: “Young entrepreneurs in decline, but Edmonton bucks trend” published FEBRUARY 27, 2015
Rakesh Soni of LoginRadius (TEC Centre tenant, TEC Edmonton client and TEC VenturePrize past finalist) was recently interviewed on CBC Radio’s Edmonton AM.

NanoSpeed Announces Global Distribution Partnership with DiaSys Diagnostics Systems for Test4D™

NanoSpeed LogoEdmonton, Alberta — (March 2, 2015)NanoSpeed Diagnostics, Inc. (“NanoSpeed”) is pleased to announce an expansion of their exclusive distribution agreement with global diagnostics and instrumentation distributor, DiaSys Diagnostics Systems GmbH (“DiaSys”), to market their 25-OH Vitamin D deficiency test kit.  Under the broadened agreement, DiaSys will market the point-of-care vitamin D test under their own brand, QDx™, worldwide except in those territories that are already part of NanoSpeed’s network and certain other territories.  DiaSys is a large point-of-care diagnostics technology company with locations in Europe, Asia and Latin America selling to over 100 countries.

“An important element of positioning our point-of-care vitamin D test to meet the needs of patients is having broad and diverse distribution,” said Dr. Seema Gupta, President of NanoSpeed Diagnostics, Inc., a leading diagnostics company focused on providing portable, innovative and rapid testing solutions.  “DiaSys has tremendous global reach and an unparalleled passion for safe and high-quality tests to bring the best result for patients.  This agreement is an important milestone for our company and patient access to our vitamin D test.  We would like to acknowledge the assistance of TEC Edmonton for their business development support.”

Technical support, advisory services and financial support from the National Research Council of Canada Industrial Research Assistance Program (“NRC-IRAP”), along with the contributions from Western Economic Diversification and Alberta Innovates – Technology Futures, were crucial to the success of NanoSpeed and its products.

NanoSpeed’s vitamin D test is a patented and unique point-of-care test that provides information on Vitamin D deficiency within 10 minutes.  This test requires only a single drop of blood from the patient and costs 90% less when compared to other standard or conventional tests.

Test4D® and QDx™ are not approved for commercial use in Canada or the United States and is limited by federal law to research or investigational use only.


About DiaSys Diagnostics Systems GmbH

DiaSys Diagnostic Systems is a leading specialist in the development and manufacturing of diagnostic system solutions of highest quality, trusted by customers in more than 100 countries for over 20 years. Our product portfolio comprises more than 90 clinical chemistry and immunoturbidimetric reagents for routine and special diagnostics including suitable calibrators and controls. The DiaSys instrumentation product range covers automated clinical chemistry analyzers, semi-automated analyzers and point of care (POC) instruments for near-patient testing.

DiaSys decided to focus further into POC: this strategic investment with global intent includes R&D, manufacturing and a portfolio of solutions, recently presented, under the QDx brand.

For more information, please visit www.diasys-diagnostics.com.


About NanoSpeed Diagnostics Inc.

NanoSpeed, incorporated in 2009, develops proprietary diagnostic/screening test kit platforms based on their Lateral Flow Immuno Assay and Lab-on-a-Chip technologies. These technological advancements provide patients with cost effective and reliable testing tools that will address the increasing needs of the healthcare industry, regulatory agencies and consumers.

About Vitamin D deficiency and Test4D™:
Vitamin D deficiency is a common problem in Canada, where 60% of adults have suboptimal levels of 25-OH vitamin D. Vitamin D deficiency has been associated with abnormalities in absorption of calcium, phosphorus, and bone metabolism; cardiovascular disease; diabetes; cancer; osteomalacia and osteoporosis in adults; and rickets in children. Deficient vitamin D levels are typically the result of an inadequate intake of vitamin D through sunlight, diet, or supplements, or due to malabsorptive disorders.

25-OH vitamin D levels are currently measured through laboratory testing. Over the past decade, there has been an incremental surge in the demand for vitamin D testing, resulting in increasing costs to government supported healthcare systems. An alternative to laboratory testing is Point-of-Care-Testing (POCT), medical testing that occurs outside of a clinical laboratory and near the patient. Potential advantages of POCT include reduction in errors and costs to the healthcare system, and the provision of quick clinical diagnoses.

To address the demands of vitamin D testing, NanoSpeed Diagnostics Inc. developed Test4D™, a POCT device for the qualitative detection of 25-OH Vitamin D in human blood obtained via fingertip puncture.

Test4D™ is available for commercial sale through certain distributors, or can be purchased for research purposes directly from NanoSpeed.



NanoSpeed Diagnostics Inc.
Seema Gupta, 780-701–0022 x 222

Posted: Nov 20, 2019

N-Doped Carbon Materials – Making Use of Eggshell Membranes

Description Nitrogen – rich carbon materials are useful for applications such as supercapacitors, battery electrodes, oxygen reduction reaction supports for polymer electrolyte membrane (PEM) fuel cells and directed methanol fuel......

Posted: Nov 19, 2019

Virtual Reality Vision Loss Experience

Description Researchers at the University of Alberta Department of Ophthalmology and Visual Sciences have developed a virtual reality (VR) game that allows players to experience the challenges of coping with......

Posted: Nov 8, 2019

Novel Potential Anti-Psychotic Agents

Description Researchers at the University of Alberta have designed a number of analogues of ßphenylethylidenehydrazine (PEH), two of which cause considerable increase of glycine in the brain in ex vivo......

Posted: Oct 18, 2019

Predicting Residual Oil Saturation During Enhanced Oil Recovery

Description The main purpose of any enhanced oil recovery (EOR) scheme is to increase the amount of oil recovered from the reservoir typically following a secondary recovery scheme such as......

Posted: Oct 3, 2019

A Novel Gene Singature to Predict Hormone Response in ER+ Breast Cancer Patients

Description Researchers at the University of Alberta have developed a novel gene expression signature to predict how a postmenopausal breast cancer patient with an estrogen receptor positive tumour will respond......

Posted: Sep 9, 2019

New Topical Therapy for Proliferative Skin Disorders

Description Dr. Afsaneh Lavasanifar and collaborators have developed a PCBCL–b-PEG-b-PCBCL (PolyGelTM) hydrogel formulation of silibinin which provides enhanced skin permeabiity and delayed release of silibinin under physiological conditions. In vitro......

Posted: Aug 28, 2019

A Self Driven, Boost Converter for Low Voltage Applications

Description Low power energy harvesting circuits often have unstable energy sources and require some kind of stabilizing circuitry to stabilize the output voltage for meaningful applications. Conventional converters either require......

Posted: Aug 27, 2019

Biodegradable Protein Based Tailings Flocculant

Description A by-product of bitumen extraction, mature fine tailings (MFT) are a mixture of fine solid clay, mineral particles and suspended hydrocarbons. MFT stable dispersion can last for decades and......

Posted: Aug 12, 2019

Telebivudine to Abrogate Amyotrophic Lateral Sclerosis

Description Telbivudine Dr. Ted Allison and his team at the University of Alberta have discovered that telbivudine, a blood brain barrier-permeable thymidine analogue approved for treatment of Hepatitis B, is......

Posted: Jun 14, 2019

A Point-of-Care Diagnostic Tool to Replace Chest X-Ray for the Diagnosis of Childhood Pneumonia

Description University of Alberta researchers have discovered a novel set of biomarkers which can be used to diagnose pneumonia in children. The biomarkers include chitinase-3-like-1 (CHI3L1), lipocalin-2 (LCN-2), C-reactive protein......

Posted: Jun 14, 2019

Novel Cell Isolation Method for Bio-engineering Artificial Cartilage

Description University of Alberta researchers have developed a new method to isolate cells from knee joint (meniscus). The isolated cells are non-contractile in nature and do not form scar tissue.......

Posted: Jun 13, 2019

Novel Composite Monolith as a New Solid Phase Extraction Material for Environmental Analysis

Description University of Alberta researchers have developed a new material of a composite silica monolith nested in sponge (SiMNS) for solid phase extraction. The application of the new SiMNS material......